Methods of overcoming treatment resistance in colorectal cancer

Simple item page
dc.contributor.authorTemraz, Sally N.
dc.contributor.authorMukherji, Deborah M.
dc.contributor.authorAlameddine, Raafat S.
dc.contributor.authorShamseddine, Ali I.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:42:58Z
dc.date.available2025-01-24T11:42:58Z
dc.date.issued2014
dc.description.abstractMetastatic colorectal cancer remains a lethal disease with a poor prognosis in the majority of patients. Multiple drug combinations have been developed in recent years that have significantly improved response rates and overall survival however resistance to these drugs is inevitable. Novel agents are currently being developed and participation in clinical trials should be encouraged. In the absence of other treatment options in a patient with good performance status, there is compelling evidence for re-challenging with previously administered agents in different combinations. The aim of this review is to discuss mechanisms of resistance and methods to overcome treatment resistance in patients with metastatic colorectal cancer who are refractory to 5-FU, irinotecan, oxaliplatin, cetuximab and bevacizumab therapy. © 2013 Elsevier Ireland Ltd.
dc.identifier.doihttps://doi.org/10.1016/j.critrevonc.2013.08.015
dc.identifier.eid2-s2.0-84892498433
dc.identifier.pmid24075059
dc.identifier.urihttp://hdl.handle.net/10938/30156
dc.language.isoen
dc.relation.ispartofCritical Reviews in Oncology/Hematology
dc.sourceScopus
dc.subject5-fluorouracil
dc.subjectBevacizumab
dc.subjectCetuximab
dc.subjectDrug resistance
dc.subjectIrinotecan
dc.subjectOvercome resistance
dc.subjectOxaliplatin
dc.subjectRe-challenge
dc.subjectAntibodies, monoclonal, humanized
dc.subjectAntineoplastic agents
dc.subjectAntineoplastic combined chemotherapy protocols
dc.subjectCamptothecin
dc.subjectColon
dc.subjectColorectal neoplasms
dc.subjectDrug resistance, neoplasm
dc.subjectFluorouracil
dc.subjectHumans
dc.subjectOrganoplatinum compounds
dc.subjectRectum
dc.subjectAflibercept
dc.subjectB raf kinase
dc.subjectCapecitabine
dc.subjectEpidermal growth factor receptor
dc.subjectExcision repair cross complementing protein 1
dc.subjectFolinic acid
dc.subjectK ras protein
dc.subjectLapatinib
dc.subjectPhosphatidylinositol 3 kinase
dc.subjectPhosphatidylinositol 3,4,5 trisphosphate 3 phosphatase
dc.subjectRegorafenib
dc.subjectRibonucleotide reductase
dc.subjectSorafenib
dc.subjectThymidylate synthase
dc.subjectCancer chemotherapy
dc.subjectCancer combination chemotherapy
dc.subjectCancer growth
dc.subjectCancer resistance
dc.subjectColorectal cancer
dc.subjectContinuous infusion
dc.subjectDiarrhea
dc.subjectDisease course
dc.subjectDisease severity
dc.subjectDna repair
dc.subjectDose response
dc.subjectDrug dose escalation
dc.subjectDrug efficacy
dc.subjectDrug exposure
dc.subjectDrug megadose
dc.subjectDrug potentiation
dc.subjectDrug targeting
dc.subjectEnzyme activity
dc.subjectEnzyme inhibition
dc.subjectFatigue
dc.subjectGene mutation
dc.subjectHuman
dc.subjectLong term exposure
dc.subjectMetastatic colorectal cancer
dc.subjectMonotherapy
dc.subjectNausea
dc.subjectNeurotoxicity
dc.subjectNeutropenia
dc.subjectNonhuman
dc.subjectOncogene k ras
dc.subjectOverall survival
dc.subjectPhase 2 clinical trial (topic)
dc.subjectPhase 3 clinical trial (topic)
dc.subjectProgression free survival
dc.subjectRash
dc.subjectReview
dc.subjectSkin manifestation
dc.subjectTreatment response
dc.subjectUnspecified side effect
dc.subjectVomiting
dc.subjectWild type
dc.titleMethods of overcoming treatment resistance in colorectal cancer
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2014-10627.pdf
Size:
1.45 MB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine